Introduction
============

Gastric Cancer (GC) was the fourth malignant tumor in the world, and the second common cause of cancer-related death. It was estimated that a total of 989600 new stomach cancer cases and 738000 deaths had occurred in 2008.[@B1] Besides, 35% of patients presented with evidence of distant metastases at the time of diagnosis, and 4% to 14% had metastatic disease to the liver, the most common metastatic organ. [@B2]-[@B6] For the complexity of gastric cancer with liver metastases (GCLM), it did not have effective treatment and its treatment strategy was still controversial. [@B6], [@B7] The median survival time of GCLM was 2-3 months in unselected patients and the 5-year survival rate was 0 to 10%. [@B3]-[@B6] Liver metastases (LM) were associated with poor survival in patients with advanced gastric cancer because of the impairment of vital organ function and increasing tumor burden to lethal levels. [@B8]-[@B10]

A population-based estimate relating to the proportion and prognosis of liver metastases at diagnosis of gastric cancer was lacking. Previous studies [@B2]-[@B6], [@B11]-[@B15] that described the frequency and clinicopathological features of liver metastases from gastric cancer had yielded varying results, from which the risk factors and prognostic factors about GCLM were not enough clear. Although most research [@B16]-[@B24] showed that patients with GCLM had a survival benefit from chemotherapy, surgery and radiotherapy, there were a few researches [@B3], [@B25] which had different sounds. Thus, the treatment strategy of GCLM was yet controversial. Besides, data at present about GCLM were almost from single institution experiences with small sample. [@B2], [@B3], [@B5], [@B8], [@B12]-[@B14], [@B18]-[@B26] Therefore, a study based on population level with more detail information about GCLM to describe epidemiologic characteristics and prognosis was urgently needed.

It was reported that for the liver metastases, MRI was the optimal diagnostic modality for evaluation of suspected hepatic metastases [@B27], which was more superior than CT and PET-CT that often could not identify some occupying [@B27]-[@B29], particularly when it was smaller than 1.0cm. However, MRI was not recommended routine assessment in current gastric cancer screening guidelines. We chose it only when patients were allergic to iodine or there was a suspicion of liver occupying on CT. Thus, some GCLM were detected during surgery or were not found at first visit, which might increase unnecessary treatment. Furthermore, MR imaging provided a precise non-radiation based imaging test for detection of liver metastases which could alter patient management and result in significant cost savings by reducing unnecessary laparotomy. [@B27]-[@B29]

In this study, we used data from the Surveillance, Epidemiology, and End Results (SEER) database from 2010-2014 to characterize the incidence proportion of liver metastases at the time of cancer diagnosis among patients with gastric cancer on a population-based level. We also wanted to characterize prognostic factors on the survival of patients with liver metastases at the time of cancer diagnosis. Furthermore, we would like to compare the significance of different treatment on GCLM in order to provide guidelines for treatment of LM in GC patients.

Materials and Methods
=====================

Database
--------

Data was obtained from SEER database, which was the largest publicly available cancer dataset and collected cancer data from 18 population-based cancer registries covering about 28 percent of the United States population.[@B30] This database included information about cancer incidence as well as demographic information: age, sex, race, year at diagnosis, tumor staging, tumor size, treatment, marital status, insurance, education, family income and so on. We used the SEERStat published by SEER to identify eligible patients in this study, which we could get from the official network (<https://seer.cancer.gov/>). The SEER database provided patients information up to 2014 based on the November 2016 submission, and it started to release metastatic information related to liver metastases from 2010. Thus, we can get information about GCLM between 1 January 2010 and 31 December 2014.

Study population
----------------

Within the SEER database, we identified 151909 patients with gastric cancer. Among these patients, we focused on 28559 patients for whom with clear information about liver metastases. Patients with other cancer, less than 18 years old, or with other pathological type were excluded from the analysis, leaving 20761 patients in the final cohort for proportion analysis. Of these, 7948 patients were diagnosed with metastases to any distant site and 3507 patients were diagnosed as GCLM. The percentage of distant metastases was 38.28% and liver metastasis was 16.89%. Data extraction flowchart was showed in Figure [S1](#SM0){ref-type="supplementary-material"}. The inclusion criteria were as follows: age more than 18 years old at time of diagnosis; gastric cancer as the only one malignant tumor; with identified information about liver metastases; with clear survival time; confirmation of diagnosis based on pathology of a specimen, rather than based on death certificate or autopsy; with active follow-up. And we excluded those patients conformed to one of the following standards: age less than 18 years old at the time of diagnosis; with other cancer except for gastric cancer; without identified information about liver metastases; pathological type confirmed to be neuroendocrine carcinoma, GIST, sarcoma or lymphoma; without clear survival time; confirmation of diagnosis based on death certificate or autopsy; without active follow-up.

We made the descriptive statistics to examine the baseline characteristics of the patient population that were stratified by year at diagnosis, age, sex, race, original, tumor location, pathology grade, Lauren classification, T staging, N staging, tumor size, sequence of radiotherapy and surgery, treatment and other sociodemographic information, such as: marital status, residence type, insurance situation, bachelor education, median household income and smoking status.

Age was divided into 4 intervals (18-40, 41-65, 66-80, 80+ years old). Race contained white, black and others (including Asian and American Indians). Original was divided into Spanish-Hispanic-Latino and Non-Spanish-Hispanic-Latino. Tumor location included the upper, middle, lower, overlapping lesion of stomach and unknown. Pathology grade of cancer was classified into 5 categories: well differentiated (Grade I), moderately differentiated (Grade II), poor differentiated (Grade III), Undifferentiated (Grade IV) and unknown. Lauren classification [@B31] was divided into intestinal-type, diffuse-type and others. The TNM staging was classified according to the seventh edition of the AJCC Cancer Staging manual of the American Joint Committee on Cancer (AJCC).[@B32] T staging included Tis, T1, T2, T3, T4 and unknown. N staging included N0, N1, N2, N3 and unknown. Tumor size was divided into 5 intervals (0-1cm, 1-2cm, 2-5cm, 5+cm, unknown). Surgery was defined as gastrectomy (C10-C50) and radical gastrectomy in continuity with the resection of other organs (RGCWROO) (C60-C63). Sequence of radiotherapy and surgery included 4 types: radiotherapy before surgery, radiotherapy after surgery, radiotherapy before and after surgery and others. Treatment was reclassified into 8 categories: patients receiving all these three treatment \-- radiotherapy, surgery and chemotherapy (RSC), or patients receiving radiotherapy and surgery (RS), or patients receiving chemotherapy and surgery (SC), or patients receiving radiotherapy and chemotherapy (RC), or patients only receiving radiotherapy (R), or patients only receiving surgery (S), or patients only receiving chemotherapy(C) and patients had not received any treatment above (Others). Residence type included 3 kinds (rural, urban and Metropolitan). Marital Status was divided into married, single, divorced, widowed and unknown. Educational level was defined as an increase of 10% of the bachelor education in the region. Median household income was defined as an increase of every \$20000. Smoking status was defined as an increase of every 10%. Residence type, education level, median household income and smoking status were defined by the county attributes from the US Census 2010-2014 American Community Survey 5-year data files, which we could get from the SEER\*Stat software.

Statistical analysis
--------------------

Descriptive statistics was used to calculate the absolute number and percentage among patients with liver metastases at the time of cancer diagnosis. Incidence proportion was defined as the percentage of gastric cancer patients diagnosed with liver metastases among the entire study cohort and the patients with metastatic disease to any distant site. All data were stratified by age, race, sex and so on. Multivariable logistic regression was used to determine predictors of the presence of liver metastases at diagnosis. Survival estimates were obtained according to the Kaplan-Meier method and compared using the log-rank test. Variables that reached significance with P \< 0.05 were entered into the multivariable analyses using the Cox regression model to identify covariates associated with increased all-cause mortality.

In the Cox regression model, we used the model 1 and 2 for analysis, separately. The model 1 contained the following variables: year at diagnosis, age, sex, tumor location, pathology grade, Lauren classification, T staging, N staging, tumor size, number of extrahepatic metastatic sites to bone, lung and brain, surgery, chemotherapy, radiotherapy, sequence of radiotherapy and surgery, marital status, insurance situation, residence type, median household income, bachelor education and smoking status. In the model 2, we used treatment (RSC, RS, SC, RC, R, S, C, Others) to replace three variables (surgery, chemotherapy and radiotherapy), and other variables were same to the model 1.

All statistical analyses were performed using SPSS statistical software (version 18.0). Statistical significance was set at two-sided (P \< 0.05).

Results
=======

Patient characteristics
-----------------------

A total of 20761 patients in the U.S. were diagnosed with gastric cancer between 2010 and 2014, including 3507 patients diagnosed with GCLM whose median age was 66 years old, consisted of 2493 men (71.08%) and 1014 women (28.91%). Their demographic and clinical characteristics were shown in Table [1](#T1){ref-type="table"}.

Proportion
----------

Among the 20761 patients in the United States diagnosed with gastric cancer between 2010 and 2014, 7948 (38.28%) presented with synchronous metastases, and 3507 (16.89%) presented with synchronous liver metastases identified at the time of diagnosis.

On univariable logistic regression (Table [S1](#SM0){ref-type="supplementary-material"}) among the entire cohort, there were sixteen factors that showed significance (P value \<0.05). They were age, race, sex, original, tumor location, pathology grade, Lauren classification, T staging, N staging, tumor size, number of extrahepatic metastatic sites to bone, lung, and brain, marital status, insurance situation, bachelor education, current smoking status and ever smoking status. We put them on multivariable logistic regression which showed that age, race, sex, original, tumor location, pathology grade, Lauren classification, T staging, N staging, tumor size, number of extrahepatic metastatic sites to bone, lung, and brain, insurance situation and current smoking status had significance among the entire cohort and age, race, sex, original, tumor location, pathology grade, Lauren classification, T staging, N staging, number of extrahepatic metastatic sites to bone, lung, and brain had significance among the subset with metastatic disease to any distant site.

On the multivariable logistic regression (Table [2](#T2){ref-type="table"}) among the entire cohort, male (vs female, OR, 1.301; 95%CI, 1.186-1.428; P\<0.001), age 41-65 years (vs age 18-40 years; OR, 1.364; 95%CI, 1.088-1.710; P=0.007), age 66-80 years (vs age 18-40 years; OR, 1.418; 95%CI, 1.125-1.787; P=0.003) and age 80+ years (vs age 18-40 years; OR, 1.015; 95%CI, 0.791-1.304; P\>0.05), black (vs others; OR, 1.562; 95%CI, 1.335-1.828; P\<0.001) and white (vs others; OR, 1.261; 95%CI, 1.107-1.436; P\<0.001), Hispanic (vs Non-Hispanic; OR, 1.200; 95% CI, 1.067-1.350; P= 0.002), grade II (vs grade I; OR, 3.058; 95%CI, 2.328-4.018; P\<0.001), grade III (vs grade I; OR, 2.544; 95%CI, 1.946-3.327; P\<0.001) and grade IV (vs grade I; OR, 2.160; 95%CI, 1.364-3.420; P=0.001), intestinal-type (vs diffuse-type; OR, 3.234; 95%CI, 2.876-3.637; P\<0.001) and others (vs diffuse-type; OR, 2.172; 95%CI, 1.644-2.870; P\<0.001), N1 (vs N0; OR, 1.977; 95%CI, 1.786-2.187; P\<0.001), N2 (vs N0; OR, 1.015; 95%CI, 0.839-1.226; P\>0.05), tumor size 1-2cm (vs tumor size 0-1cm; OR, 1.332; 95%CI, 0.915-1.938; P \>0.05), tumor size 2-5cm (vs tumor size 0-1cm; OR, 2.628; 95%CI, 1.900-3.633; P\<0.001) and tumor size 5+cm (vs tumor size 0-1cm; OR, 3.419; 95%CI, 2.462-4.748; P\<0.001), 1 extrahepatic metastatic site (vs 0 extrahepatic metastatic site; OR, 2.842; 95%CI, 2.522-3.202; P\<0.001), 2 extrahepatic metastatic sites (vs 0 extrahepatic metastatic site; OR, 4.416; 95%CI, 3.371-5.785; P\<0.001), 3 extrahepatic metastatic sites (vs 0 extrahepatic metastatic site; OR, 5.323; 95%CI, 1.773-15.980; P=0.003), without insurance (vs with insurance; OR, 1.680; 95%CI, 1.215-2.325; P=0.002), current smoking per 10% increased (OR, 1.161;95%CI, 1.046-1.288; P=0.005) were associated with significantly greater odds of having liver metastases at diagnosis. While, marital status, bachelor education and ever smoking status was not associated with a risk of liver metastasis at diagnosis in the multivariable model. And middle of stomach (vs upper of stomach; OR, 0.761;95%CI, 0.650-0.890; P= 0.001), lower of stomach (vs upper of stomach; OR, 0.703; 95%CI, 0.621-0.795; P\<0.001) and overlapping lesion (vs upper of stomach; OR, 0.769; 95%CI, 0.649-0.912; P=0.003), T2 (vs T1; OR, 0.311; 95%CI, 0.247-0.391; P\<0.001), T3 (vs T1; OR, 0.388; 95%CI, 0.335-0.448; P\<0.001) were associated with marginally lower odds of liver metastasis at diagnosis. The multivariable logistic regression of subset with metastatic disease was also showed in Table [2](#T2){ref-type="table"}.

From the finding above, it seemed that GC patients with factors like higher age, male, the black and white race, Hispanic, intestinal-type, later N staging, poor tumor grade, upper of stomach, presence of more extrahepatic metastatic sites, larger tumor, absence of insurance and heavy smoking had higher risk to develop liver metastases.

Survival
--------

On univariate analysis for all-cause mortality among the subset with liver metastases, there were eighteen factors that were significantly associated with overall survival (P value \<0.05). Table [S2](#SM0){ref-type="supplementary-material"} showed univariate analysis for all-cause mortality among GCLM. They were year at diagnosis, age, tumor location, Lauren classification, T staging, N staging, tumor size, number of extrahepatic metastatic sites to bone, lung, and brain, surgery, chemotherapy, radiotherapy, sequence of radiotherapy and surgery, treatment, marital status, residence type, median household income, bachelor education and current smoking status. We put them on Cox regression model which showed that age, tumor location, Lauren classification, T staging, number of extrahepatic metastatic sites to bone, lung, and brain, surgery, chemotherapy and marital status were significantly associated with overall survival in the model 1 (Table [3](#T3){ref-type="table"}) and age, tumor location, Lauren classification, T staging, number of extrahepatic metastatic sites to bone, lung, and brain, treatment, marital status and residence type were significantly associated with overall survival in the model 2 (Table [3](#T3){ref-type="table"}). We put RSC, C and Others as comparison standard in the model 2 separately in order to explain the significance of different treatments, which was showed in Table [S3](#SM0){ref-type="supplementary-material"}.

On multivariable Cox regression for all-cause mortality among patients with GCLM at diagnosis, overlapping lesion of stomach (vs upper of stomach; HR, 1.292; 95%CI, 1.111-1.503; P=0.001), diffuse-type (vs intestinal-type; HR,1.204; 95%CI, 1.076-1.348; P=0.001) and others (vs intestinal-type; HR,1.476; 95%CI, 1.178-1.850; P=0.001), 1 extrahepatic metastatic site (vs 0 extrahepatic metastatic site; HR, 1.362; 95%CI, 1.240-1.497; P\<0.001), 2 extrahepatic metastatic sites (vs 0 extrahepatic metastatic site; HR, 1.476; 95%CI, 1.212-1.798; P\<0.001), single (vs married; HR, 1.150; 95%CI, 1.038-1.274;P=0.008) and divorced (vs married; HR, 1.153; 95%CI, 1.012-1.314;P=0.033), without chemotherapy (vs chemotherapy; HR, 3.064; 95%CI, 2.818-3.332; P\<0.001), without surgery (vs with gastrectomy only; HR, 1.899; 95% CI, 1.574-2.293; P\<0.001) and refuse surgery (vs with gastrectomy only; HR, 1.813; 95%CI, 1.109-2.965; P=0.018), C (vs RSC; HR, 1.375; 95%CI, 0.879-2.153; P=0.163) S (vs SC; HR, 1.929; 95%CI, 1.184-3.145; P=0.008) and others (vs RSC; HR,4.607; 95%CI, 2.938-7.224; P\<0.001) were significantly associated with an increased all-cause mortality. And year at diagnosis, N staging, radiotherapy, sequence of radiotherapy and surgery, tumor size, residence type, bachelor education, median house income and current smoking status were not associated with all-cause mortality. However, age 18-40 years (vs age 80+ years; HR, 0.798; 95%CI, 0.630-0.997; P=0.047), age 41-65 years (vs age 80+ years; HR, 0.746; 95%CI, 0.660-0.843; P\<0.001), age 66-80 years (vs age 80+ years; HR, 0.834; 95%CI, 0.742-0.937; P=0.002), T2 (vs T1; HR, 0.712; 95%CI, 0.559-0.906; P=0.006) and SC (vs C; HR, 0.650; 95%CI, 0.492-0.857; P=0.002) were significantly associated with an decreased all-cause mortality. All data except for treatment came from the model 1.

In general, it seemed that higher age, overlapping lesion, diffuse-type, absence of surgery, absence of chemotherapy, and presence of more extrahepatic metastatic sites, unmarried (single and divorced) were associated with poor prognosis in GCLM.

Patient management
------------------

Among GCLM, number of patients with and without radiotherapy were 542 (15.45%) and 2965 (84.55%), with and without chemotherapy were 1869 (53.29%) and 1638 (46.71%), with, without and refuse surgery were 252 (7.19%), 3234 (92.22%) and 21 (0.60%), separately. Based on these three, we had reclassified different treatment. The patients with RSC, RS, SC, RC, R, S, C and others were 30 (0.86%), 5 (0.14%), 96 (2.74%), 359 (10.24%), 148 (4.22%), 121 (3.45%), 1384 (39.46%) and 1364 (38.89%). Venn diagram was made to visualize these data (Figure [S2](#SM0){ref-type="supplementary-material"}). (Venny\'s on-line reference: <http://bioinfogp.cnb.csic.es/tools/venny/index.html>)

Besides, among the entire cohort, 2781 (13.40%), 130 (0.63%), 7969 (9.48%), 1975 (9.51%), 598 (2.88%), 4001 (19.27%), 4065 (19.58%) and 5242 (25.25%) of GC had been treated with RSC, RS, SC, RC, R, S, C and others, respectively. Among the cohort with metastatic disease, 130 (1.64%), 15 (0.19%), 412 (5.18%), 816 (10.27%), 324 (4.08%), 330 (4.15%), 3191 (40.15%) and 2730 (34.35%) of GC had been treated with RSC, RS, SC, RC, R, S, C and others, respectively. Among the cohort with metastatic disease except liver, 100 (2.25%), 10 (0.23%), 316 (7.12%), 457 (10.29%), 176 (3.96%), 209 (4.71%), 1807 (40.69%) and 1366 (30.76%) of GC had been treated with RSC, RS, SC, RC, R, S, C and others, respectively. The proportion of patients with GCLM receiving RSC, SC, S was significantly lower than patients of entire cohort. The treatment among patients with distant metastasis, with distant metastatic disease except for the liver or with liver metastasis was similar (Figure [S3](#SM0){ref-type="supplementary-material"} and Figure [S4](#SM0){ref-type="supplementary-material"}).

The median survival time of the SEER cohort included in the survival analysis was 4.0 months (IQR: 1.0-10.0 mo) (Figure [1](#F1){ref-type="fig"}A). Median survival time among GCLM patients treated with chemotherapy was 8.0 months (IQR: 4.0-15.0 mo), among those without chemotherapy was 1.0 month (IQR: 0.0-3.0 mo) (Figure [1](#F1){ref-type="fig"}B). Median survival time with radical gastrectomy in continuity with the resection of other organs was 12.0 months (6.0-NA mo), with gastrectomy only was 8.0 months (IQR: 2.0-19.0 mo), without surgery was 3.0 months (IQR: 1.0-10.0 mo) and among those who refused surgery although they were recommended was 1.0 month (IQR: 0.0-5.0 mo) (Figure [1](#F1){ref-type="fig"}C). Median survival time with radiation therapy was 6.0 months (IQR: 2.0-11.0 mo), and without radiation therapy was 3.0 months (IQR: 1.0-10.0 mo). Median survival time among patients treated with RSC was 12.0 months (IQR: 6.0-17.0mo), with RS was 1.0 months (IQR: 1.0-4.0mo), with SC was 12.0 months (IQR:6.0-31.0mo), with RC was 7.0 months (IQR: 4.0-13.0mo), with R was 2.0 months (IQR: 1.0-3.0mo), with S was 4.0 months (IQR: 1.0-12.0mo), with C was 8.0 months (IQR: 4.0-15.0mo), with others was 1.0 month (IQR:0.0-3.0mo) (Figure [1](#F1){ref-type="fig"}D). Survival estimates stratified by extent of extrahepatic metastases were displayed in the Figure [2](#F2){ref-type="fig"} as supplementary.

Our study also found that the 6 month, 1, 2, and 3-year survival rate (Table [S4](#SM0){ref-type="supplementary-material"} and Figure [S5](#SM0){ref-type="supplementary-material"}) of GCLM treated with RSC were 74.2%, 45.3%, 17.2% and 17.2% respectively, with RS were 17.9%, 17.9%, 17.9% and 17.9% respectively, with SC were 72.5%, 47.5%, 27.7% and 22.1% respectively, with RC were 53.9%, 25.1%, 6.6% and 4.9% respectively, with R were 11.3%, 3.5%, 2.7% and 1.8% respectively, with S were 37.0%, 23.1%, 13.2% and 11.3% respectively, with C were 57.1%, 32.0%, 12.4% and 5.6% respectively, with others were 10.2%, 3.8%, 1.7% and 1.0% respectively.

The result showed that patients receiving positive treatment had a significantly benefit on the first 3-year accumulate survival rate. The prognosis of patients treated with RSC or SC was best, while patients who received other treatments had the worst prognosis.

Discussion
==========

In this study, we described the proportion and survival of gastric cancer patients who had liver metastases at their initial diagnosis, based on available data from the SEER database. Because early detection and comprehensive therapy of liver metastases may alter the natural progression of gastric cancer, and improve overall survival, quality of life and cost savings, it was important for us to study patients who presented with de novo GCLM in a large independent cohort.

We found that 16.89% of patients with gastric cancer had liver metastases at diagnosis, and 44.12% of those with any metastases at diagnosis had liver metastases. This result was a little higher than that of previously published study [@B2]-[@B6], and was similar to that of a previous study using SEER database.[@B11]

We identified predictors of the presence of liver metastases at diagnosis using multivariate logistic regression to distinguish patients at increased risk of liver metastases. This study found that male, the black and white race, intestinal-type, poor tumor grade, upper of stomach, more extrahepatic metastatic sites and absence of insurance increased risk to be GCLM among the entire cohort, which was same to the study published before.[@B4], [@B6], [@B33] Furthermore, we also found that patients with higher age, Hispanic, larger primary tumor and heavy smoking were easier to be GCLM, which had not been reported before as we known. However, our study showed that only N1 had higher risk to be GCLM and T2 or T3 had lower risk to be GCLM, which were different to the research published before.[@B6], [@B33] These research \[6, 33\]showed that the later T staging and later N staging based on pathological staging were the risk factors to be GCLM, but our study had not showed the same phenomenon. We thought that it might be because most T staging and N staging of our study were based on clinical staging, which was not accurate enough.[@B34]

The percentage of male with GCLM in the entire cohort and subset with metastatic disease were 19.04% and 48.63%, respectively, female were 13.22% and 35.94%, respectively. The proportion of male was 1.44 times to female (P\<0.001), which might owe to the bad living habit and alcoholism [@B35]. The black (19.81% and 50.28%) and white (17.40% and 44.29%) race had a significantly greater likelihood of presenting liver metastases than others (12.64% and 37.47%) (P\<0.001). The reason was unknown which need further study. For tumor pathology grade, grade II (19.77% and 63.39%), grade III (15.25% and 38.35%) and grade IV (11.36% and 36.00%) had higher proportion of liver metastasis than grade I (7.17% and 53.54%) tumors (P\<0.001). In the Lauren classification, intestinal-type (20.84% and 55.45%) had a significantly greater likelihood to be liver metastasis than diffuse-type (7.45% and 18.63%) (P\<0.001). Takahashi et al thought it might due to higher expression of extracellular matrix metalloproteinase inducer in intestinal-type cell, which may stimulate matrix metalloproteinase and vascular endothelial growth factor expression of surrounding stromal cells, then promoted tumor growth and metastasis.[@B36] Primary tumor located at the upper of stomach (21.37% and 56.23%) had significantly higher percentage of liver metastasis, while middle (13.85% and 36.44%), lower (12.14% and 40.58%) and overlapping lesion (14.76% and 31.92%) had lower percentage of liver metastasis (P\<0.001). According to the present results [@B37]-[@B39], cardia cancer was actually more likely to metastasize to the liver compared with non-cardia cancer, which indicated a difference in biology, according to the "seed and soil" hypothesis ("seed-and-soil" hypothesis implies organ specific tropism of circulating tumor cells). Patients with lager tumor (P\<0.001) and more extrahepatic metastatic sites (P\<0.001) had significantly higher rate of liver metastasis, too. Because gastric cancer spread to the liver primarily through hematogenous dissemination, lymphatic dissemination, and serosal invasion from the tumor tissue, large tumor had more chance to occur vessel, lymphatic system and serosal invasion, then to develop liver metastases.[@B6] Besides, the liver metastatic rate in uninsured patients (20.52%) was higher than insured patients (16.76%) (P\<0.001). Patients with insurance might receive more early intervention and had a lower risk to develop metastatic diseases.[@B11] And patients with heavy smoking currently was easier to be GCLM (P=0.007), which might owe to these patients lack of screening according to a global research. [@B40]

This study provided a basis for future studies to evaluate the utility of MRI among these high-risk patients. From the finding above, we thought that we should pay more attention to those patients with factors like higher age, male, the black and white race, Hispanic, intestinal-type, later N staging, poor tumor grade, upper of stomach, presence of more extrahepatic metastatic sites and larger tumor, who might have higher risk of liver metastases. These patients need further examination at first diagnosis or during the patients\' disease course. And we need to encourage patients without insurance and with heavy smoking to get screening.

Our study found that higher age, overlapping lesion, diffuse-type, absence of surgery, absence of chemotherapy, and presence of more extrahepatic metastatic sites, unmarried (single and divorced) had a significant negative impact on overall survival, however T2 staging showed an opposite result. And N staging, pathology grade, tumor size, radiotherapy, sequence of radiotherapy and surgery, residence type, median household income, bachelor education, insurance status and smoking status were not associated with prognosis (Table [3](#T3){ref-type="table"}). The prognosis of single and divorced with similar HR were poorer compared with the married, but widowed showed no significant difference to the married. It was similar to the article [@B41], [@B42] published before, which thought that unmarried (single, divorced, widowed) patients may accept less treatment support because of lack of spousal support, leading to the poor survival. The phenomenon of patients with more extrahepatic metastasis sites associating with poor survival also had been reported.[@B12]-[@B14] However, patients with 3 extrahepatic metastatic sites showed not significance with prognosis in our article, which might owe to this subset with 11 patients only. The study showed that the elderly had a poorer prognosis, because the elder might be often treated with more conservative treatment for the poor basic conditions or had short natural life. It was interesting that intestinal-type GC had higher incidence of LM, but showed better survival. And we did not know why T2 showed better prognosis among patients with GCLM. Inaccuracy of clinical staging may explain it.

NCCN clinical practice guidelines in oncology (NCCN Guideline) and Japanese gastric cancer treatment guidelines 2014 (version4) recommended systemic chemotherapy based on fluorouracil or paclitaxel, supplemented by targeted therapy and best supportive therapy as the main treatment methods for advanced gastric cancer.[@B16], [@B17] However, there was still great controversial in the treatment of GCLM, because the effect of above treatment was limited. Most studies [@B16]-[@B24] showed that chemotherapy and surgery by selected patients had a positive prognosis to GCLM, which could improve the median survival time from 2-3months to 7-15months, and 40-55% patients selected might benefit from combined liver resection. What\'s more, GCLM got better benefit from combination of surgery and chemotherapy.[@B22]-[@B24] However, there were yet some research [@B3], [@B25] hold the opposite conclusion: no improvement in median survival for patients increased use of chemotherapy or surgery. And a study [@B18] published before showed that radiotherapy had a survival benefit to metastatic gastric cancer, however, we did not get the same result of our study. Furthermore, our study provided a supplement that the prognosis of GCLM was not influenced by the sequence of radiotherapy and surgery with limited data. We then thought that radiotherapy should be carefully selected if the aim was to improve median survival, although it might provide some help to the treatment of bleeding, obstruction and so on. Further investigation about the function of radiotherapy was necessary.

Among the whole study cohort, we can see that most patients received surgery (54.30%) and chemotherapy (48.07%). However, the rate of surgery was only 11.16% among the subset of metastatic disease to any distant site and 7.18% among the subset of liver metastases. Moreover, number of patients who received radical gastrectomy in continuity with the resection of other organs was only 29 (0.83%), among which 27 patients had liver metastases only and the other two concurrent with pulmonary metastases. None of them had bone or brain metastases. While the chemotherapy rate among the subset of metastatic disease (57.23%) and the subset of liver metastases (53.29%) was a little higher than the whole cohort (48.07%). Among the subset of liver metastases, 0.86%, 0.14%, 2.74%,10.24%, 4.22%, 3.45%, 39.46% and 38.89% had been treated with RSC, RS, SC, RC,R, S, C and others, separately, which was similar to the subset of metastatic disease and subset of metastatic disease to any distant site except of liver. We could see that patients with GCLM receiving RC, C and others were nearly 90%, and the surgery rate of GCLM was lower. Few patients received comprehensive therapy.

In model 1, Median survival time among GCLM increased 7 months from absence of chemotherapy to chemotherapy (P\<0.001). And median survival time increased 5 months from absence of surgery to gastrectomy, 7 months from refusing surgery to gastrectomy, 9 months from absence of surgery to RGCWROO and 11 months from refusing surgery to RGCWROO (P\<0.001). Median survival time increased 3 months from absence of radiotherapy to radiotherapy (P\>0.05). Besides, patients who received radical gastrectomy in continuity with the resection of other organs seemed to had a better median survival (12 mo) compared with gastrectomy only (8 mo), although it showed no significance (P=0.118), which need further investigation including more cases.

In model 2, median survival time among GCLM increased 11 months from others to RSC, 11 months from others to RC, 3 months from others to S, 7 months from others to C, and it had not significantly increased from others to RS or R. Moreover, the median survival time of RSC and SC was same (P=0.675). Although it showed no significant difference (P=0.162), the median survival time increased 4 months from C to RSC. And the median survival time of RSC had significant increased from RS, RC, R, S or others (P\<0.05). Besides, the median survival time increased 4 months from C to SC with significance (P=0.002). On the other hand, an aggregate 6-month survival rate estimates and 1, 2, 3-year survival rate estimates showed an absolute increase of 64%, 41.5%, 15.5% and 16.2% from others to RSC, 62.3%, 43.7%, 26% and 21.1% from others to SC, 43.7%, 21.3%, 4.9% and 3.9% from others to RC, 26.8%, 19.3%, 11.5% and 10.3% from others to S, and 46.9%, 28.2%, 10.7% and 4.6% from others to C. Furthermore, an aggregate 6-month survival rate estimates and 1, 2, 3-year survival rate estimates showed an absolute increase of 17.1%, 13.3%, 4.8% and 11.6% from C to RSC, and 15.4%, 15.5%, 15.3% and 16.5% from C to SC. The result showed that patients receiving positive treatment had a significantly benefit on the first 3-year accumulate survival rate. From the result above, it showed that patients with GCLM can get benefit from chemotherapy and surgery, especially a combination of two treatments, but radiotherapy showed no significant effect for overall survival. The median survival of patients with RSC or SC was longest, while patients with other treatments had the worst prognosis.

Although there may have some limitations of our study, we yet could make a conclusion that GCLM might get benefit from the comprehensive therapy. Chemotherapy might make the biggest survival benefit as the prime treatment. And surgery might make some help to those highly selected patients, believed to be the only radical cure. However, the importance of radiotherapy needed to be reconsidered because it showed no significant effect in this study. Aggressive treatment might make significant benefit to GCLM patients, so we need to screen more patients who were available to comprehensive therapy, based on comprehensive therapy seldom receiving by GCLM at present.

In conclusions, the findings of this study provided population-based estimates of the proportion and prognosis for GCLM at time of diagnosis. Chemotherapy and surgery made benefit to GCLM on overall survival, especially a combination of both, but radiotherapy showed not significant benefit to overall survival. And we might need to screen more patients who were available to comprehensive therapy, because comprehensive therapy was seldom received by GCLM at present.

Although our study was based on population-level, containing large of case, we should not ignore its limitations.

Firstly, we could know those patients with metastatic disease of the liver, bone, lung and brain, but the SEER database did not provide information about other metastatic sites, like peritoneal metastases. Moreover, we only had information on synchronous metastasis to liver, lack of a relative minority compared to those patients who may develop metachronous metastasis; Secondly, we could only know the patient undergo radical gastrectomy in continuity with the resection of other organs, but we did not know the clear type of organ; Thirdly, information relating to comorbidities, performance status was not available in the SEER database; Fourth, residence type, education level, and median household income were defined at a county level, not a patient level, possibly affecting the results of the logistic and Cox regressions; Fifth, the morbidity and mortality after treatment were not recorded in the SEER database; Sixth, the SEER did not record the information about the types and grading (H1,H2 and H3) of liver metastases, and the size of tumor metastases.

To the best of our knowledge, this study was the first population-based analysis of patients with liver metastases at initial diagnosis of gastric cancer. It provided important suggestion for clinicians to consider designing studies that evaluate the utility of MRI among patients with higher risk of liver metastases. The prognostic factors on GCLM were analyzed in this study too. Besides, we compared the significance of different treatment on GCLM, which might provide some help to clinical practice.
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###### 

Clinical characteristics of Patients With Gastric Cancer With Identified Liver Metastases at Diagnosis.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                      Patients, No.   Proportion of Liver Metastases, %   Survival Among Patients\                                 
                                                                                                                    With Liver Metastases,Median (IQR), mo                   
  ------------------------------------------------------------- --------------- ----------------------------------- ---------------------------------------- ------- ------- -----------------
  Year at diagnosis                                                                                                                                                          

  2010                                                          4005            1570                                696                                      17.38   44.33   3.0 (1.0-9.0)

  2011                                                          3982            1475                                700                                      17.58   47.46   4.0 (1.0-10.0)

  2012                                                          4280            1591                                671                                      15.68   42.17   3.0 (1.0-9.0)

  2013                                                          4233            1628                                745                                      17.60   45.76   4.0 (1.0-11.0)

  2014                                                          4333            1684                                695                                      16.04   41.27   5.0 (1.0-NA)

  Age at diagnosis, Y                                                                                                                                                        

  18-40                                                         929             523                                 118                                      12.70   22.56   5.0 (2.0-12.0)

  41-65                                                         8818            3875                                1588                                     18.01   40.98   5.0 (1.0-12.0)

  66-80                                                         7399            2557                                1296                                     17.52   50.68   3.0 (1.0-9.0)

  80+                                                           3615            993                                 505                                      13.97   50.86   2.0 (0.0-4.0)

  Race                                                                                                                                                                       

  White                                                         14490           5692                                2521                                     17.40   44.29   4.0 (1.0-11.0)

  Black                                                         2696            1062                                534                                      19.81   50.28   4.0 (1.0-10.0)

  Others^a^                                                     3419            1153                                432                                      12.64   37.47   3.0 (1.0-9.0)

  Unknown                                                       156             41                                  20                                       12.82   48.78   5.0 (1.0-NA)

  Sex                                                                                                                                                                        

  Male                                                          13093           5126                                2493                                     19.04   48.63   4.0 (1.0-10.0)

  Female                                                        7668            2821                                1014                                     13.22   35.94   3.0 (1.0-9.0)

  Original                                                                                                                                                                   

  Hispanic                                                      4234            1790                                598                                      14.12   33.41   4.0 (1.0-10.0)

  Non-Hispanic                                                  16527           6156                                2909                                     17.60   47.25   4.0 (1.0-10.0)

  Tumor location                                                                                                                                                             

  Upper                                                         7617            2895                                1628                                     21.37   56.23   5.0 (1.0-11.0)

  Middle                                                        1978            752                                 274                                      13.85   36.44   3.0 (1.0-10.0)

  Lower                                                         4397            1316                                534                                      12.14   40.58   3.0 (1.0-11.0)

  Overlapping lesion                                            1585            733                                 234                                      14.76   31.92   2.0 (1.0-7.0)

  Unknown                                                       5184            2252                                837                                      16.15   37.17   2.0 (1.0-7.0)

  Pathology grade                                                                                                                                                            

  I                                                             949             127                                 68                                       7.17    53.54   4.0 (1.0-14.0)

  II                                                            4537            1415                                897                                      19.77   63.39   5.0 (2.0-13.0)

  III                                                           11177           4446                                1705                                     15.25   38.35   4.0 (1.0-9.0)

  IV                                                            317             100                                 36                                       11.36   36.00   2.0 (1.0-11.0)

  Unknown                                                       3781            1860                                801                                      21.18   43.06   2.0 (1.0-9.0)

  Lauren classification                                                                                                                                                      

  Intestinal-type                                               14264           5381                                2973                                     20.84   55.25   4.0 (1.0-11.0)

  Diffuse-type                                                  5957            2383                                444                                      7.45    18.63   3.0 (1.0-8.0)

  Others^b^                                                     540             184                                 90                                       16.67   48.91   1.0 (0.0-3.0)

  Tumor staging^c^                                                                                                                                                           

  I                                                             3846            0                                   0                                        0.00    NA      NA

  II                                                            2814            0                                   0                                        0.00    NA      NA

  III                                                           4243            0                                   0                                        0.00    NA      NA

  IV                                                            7948            7948                                3507                                     44.12   44.12   4.0 (1.0-10.0)

  Unknown                                                       1910            0                                   0                                        0.00    NA      NA

  T staging^c^                                                                                                                                                               

  Tis                                                           129             41                                  16                                       12.40   39.02   1.0 (0.0-4.0)

  T1                                                            4977            1419                                728                                      14.63   51.30   3.0 (1.0-10.0)

  T2                                                            1785            360                                 97                                       5.43    26.94   6.0 (2.0-13.0)

  T3                                                            5038            1106                                400                                      7.94    36.17   6.0 (3.0-16.0)

  T4                                                            3883            1750                                641                                      16.51   36.63   4.0 (1.0-10.0)

  Unknown                                                       4949            3272                                1625                                     32.83   49.66   3.0 (1.0-9.0)

  N staging^c^                                                                                                                                                               

  N0                                                            9355            2813                                1183                                     12.65   42.05   3.0 (1.0-9.0)

  N1                                                            5541            2749                                1314                                     23.71   47.80   5.0 (1.0-11.0)

  N2                                                            1852            439                                 172                                      9.29    39.18   7.0 (2.0-15.0)

  N3                                                            1953            501                                 149                                      7.63    29.74   6.0 (2.0-14.0)

  Unknown                                                       2060            1446                                689                                      33.45   47.65   2.0 (0.0-7.0)

  M staging^c^                                                                                                                                                               

  M0                                                            12813           0                                   0                                        0.00    NA      NA

  M1                                                            7948            7948                                3067                                     38.59   38.59   4.0 (1.0-10.0)

  Surgery                                                                                                                                                                    

  Gastrectomy                                                   7029            718                                 223                                      3.17    31.06   8.0 (2.0-19.0)

  RGCWROO^d^                                                    952             169                                 29                                       3.05    17.16   12.0 (6.0-NA)

  No                                                            11273           7008                                3234                                     28.69   46.15   3.0 (1.0-10.0)

  Refuse                                                        555             53                                  21                                       3.78    39.62   1.0 (0.0-5.0)

  Radiotherapy                                                                                                                                                               

  Yes                                                           5484            1285                                542                                      9.88    42.18   6.0 (2.0-11.0)

  No                                                            15277           6663                                2965                                     19.41   44.50   3.0 (1.0-10.0)

  Chemotherapy                                                                                                                                                               

  Yes                                                           107882          4549                                1869                                     1.73    41.09   8.0 (4.0-15.0)

  No                                                            9979            3399                                1638                                     16.41   48.19   1.0 (0.0-3.0)

  Sequence of radiotherapy and surgery^e^                                                                                                                                    

  RBS                                                           1127            56                                  14                                       1.24    25.00   12.0 (9.0-NA)

  RAS                                                           1952            183                                 45                                       2.31    24.59   9.0 (2.0-16.0)

  RBAS                                                          45              2                                   1                                        2.22    50.00   NA

  Others                                                        17637           7707                                3447                                     19.54   44.73   4.0 (1.0-10.0)

  Treatment^f^                                                                                                                                                               

  RSC                                                           2781            130                                 30                                       1.08    23.08   12.0 (6.0-17.0)

  RS                                                            130             15                                  5                                        3.85    33.33   1.0 (1.0-4.0)

  SC                                                            1969            412                                 96                                       4.88    23.30   12.0 (6.0-31.0)

  RC                                                            1975            816                                 359                                      18.18   44.00   7.0 (4.0-13.0)

  R                                                             598             324                                 148                                      24.75   45.68   2.0 (1.0-3.0)

  S                                                             4001            330                                 121                                      3.02    36.67   4.0 (1.0-12.0)

  C                                                             4065            3191                                1384                                     34.05   43.37   8.0 (4.0-15.0)

  Others                                                        5242            2730                                1364                                     26.02   49.96   1.0 (0.0-3.0)

  Tumor size, cm                                                                                                                                                             

  0-1                                                           955             137                                 51                                       5.34    37.23   2.0 (0.0-7.0)

  1-2                                                           1502            243                                 100                                      6.66    41.15   5.0 (1.0-13.0)

  2-5                                                           5167            1370                                666                                      12.89   48.61   5.0 (1.0-12.0)

  5+                                                            4041            1310                                617                                      15.27   47.10   4.0 (1.0-11.0)

  Unknown                                                       9096            4888                                2073                                     22.79   42.41   3.0 (1.0-9.0)

  Extrahepatic metastatic sites to bone, lung, and brain, No.                                                                                                                

  0                                                             18406           5628                                2432                                     13.21   43.21   4.0 (1.0-11.0)

  1                                                             1657            1657                                669                                      40.37   40.37   3.0 (1.0-7.0)

  2                                                             265             265                                 136                                      51.32   51.32   2.0 (1.0-7.0)

  3                                                             17              17                                  11                                       64.71   64.71   3.0 (1.0-7.0)

  Unknown                                                       416             381                                 259                                      62.26   67.98   2.0 (0.0-7.0)

  Insurance situation                                                                                                                                                        

  Yes                                                           19271           7299                                3229                                     16.76   44.24   4.0 (1.0-10.0)

  No                                                            960             502                                 197                                      20.52   39.24   3.0 (1.0-7.0)

  Unknown                                                       530             147                                 81                                       15.28   55.10   3.0 (0.0-13.0)

  Marital status                                                                                                                                                             

  Married                                                       11782           4594                                2032                                     17.25   44.23   5.0 (1.0-11.0)

  Single                                                        3257            1405                                584                                      17.93   41.57   3.0 (1.0-8.0)

  Divorced                                                      1737            708                                 308                                      17.73   43.50   3.0 (1.0-9.0)

  Widowed                                                       2888            896                                 432                                      14.96   48.21   2.0 (1.0-6.0)

  Unknown                                                       1097            345                                 151                                      13.76   43.77   4.0 (1.0-12.0)

  Residence type                                                                                                                                                             

  Rural                                                         1546            610                                 290                                      18.76   47.54   2.0 (0.0-7.0)

  Urban                                                         346             90                                  48                                       13.87   53.33   2.0 (1.0-8.0)

  Metropolitan                                                  18869           7248                                3169                                     16.79   43.72   4.0 (1.0-10.0)

  Bachelor education (per 10% increase)                                                                                                                                      

  0-10%                                                         151             59                                  31                                       20.53   52.54   2.0 (1.0-5.0)

  10-20%                                                        3366            1332                                610                                      18.12   45.80   3.0 (1.0-9.0)

  20-30%                                                        4559            1748                                830                                      18.21   47.48   3.0 (1.0-10.0)

  30-40%                                                        8800            3307                                1356                                     15.41   41.00   4.0 (1.0-11.0)

  40-50%                                                        3302            1280                                579                                      17.53   45.23   5.0 (1.0-11.0)

  50-60%                                                        583             222                                 101                                      17.32   45.50   4.0 (1.0-10.0)

  Median household income (per \$20,000 increase)                                                                                                                            

  20,000-40,000                                                 249             88                                  46                                       18.47   52.27   2.0 (0.0-7.0)

  40,000-60,000                                                 4521            1776                                823                                      18.20   46.34   3.0 (1.0-9.0)

  60,000-80,000                                                 9465            3596                                1546                                     16.33   42.99   4.0 (1.0-10.0)

  80,000-100,000                                                4751            1820                                791                                      16.65   43.46   4.0 (1.0-11.0)

  100,000-120,000                                               1775            668                                 301                                      16.96   45.06   5.0 (1.0-12.0)

  Current smoking status (per 10% increase)                                                                                                                                  

  0-10%                                                         894             320                                 130                                      14.54   40.63   5.0 (2.0-13.0)

  10-20%                                                        13846           5296                                2255                                     16.29   42.58   4.0 (1.0-10.0)

  20-30%                                                        5585            2152                                1036                                     18.55   48.14   3.0 (1.0-9.0)

  40-50%                                                        436             180                                 86                                       19.72   47.78   3.0 (1.0-7.0)

  Ever smoking status (per 10% increase)                                                                                                                                     

  20-30%                                                        1514            603                                 255                                      16.84   42.29   4.0 (1.0-9.0)

  30-40%                                                        9971            3821                                1583                                     15.88   41.43   4.0 (1.0-11.0)

  40-50%                                                        8008            3019                                1430                                     17.86   47.37   4.0 (1.0-10.0)

  50-60%                                                        1268            505                                 239                                      18.85   47.33   3.0 (1.0-9.0)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations:

IQR: interquartilerange, CI: confidence interval, GCLM: gastric cancer with liver metastases;

^a^including Asian and American Indians;

^b^ including linitis plastica, hepatoid adenocarcinoma, adenosquamous carcinoma;

^c^ according to the seventh edition of the AJCC Cancer Staging manual;

^d^ RGCWROO: radical gastrectomy in continuity with the resection of other organs;

^e^ including RBS: radiotherapy before surgery, RAS: radiotherapy after surgery, RBAS: radiotherapy before and after surgery, others: without radiotherapy or surgery or unknown sequence;

^f^ including RSC: radiotherapy, surgeryandchemotherapy, RS: radiotherapy and surgery, SC: chemotherapy and surgery, RC: radiotherapy and chemotherapy, R: only radiotherapy, S: only surgery, C: only chemotherapy, others: other treatmentexcept for radiotherapy, surgery and chemotherapy.

###### 

Multivariable Logistic Regression for the Presence of Liver Metastases at Diagnosis of Gastric Cancer.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                      Patients, No.                                 Among Entire Cohort                         
  ------------------------------------------------------------- --------------- ------ ---------------------- --------------------- --------------------- ---------
  Age at diagnosis, Y                                                                                                                                     

  18-40                                                         929             118    1 (Reference)          NA                    1 (Reference)         NA

  41-65                                                         8818            1588   1.364 (1.088-1.710)    0.007                 1.577 (1.243-2.001)   \<0.001

  66-80                                                         7399            1296   1.418 (1.125-1.787)    0.003                 2.155 (1.683-2.760)   \<0.001

  80+                                                           3615            505    1.015 (0.791-1.304)    0.905                 2.005 (1.520-2.645)   \<0.001

  Race                                                                                                                                                    

  Others^a^                                                     3419            432    1 (Reference)          NA                    1 (Reference)         NA

  White                                                         14490           2521   1.261 (1.107-1.436)    \<0.001               1.197 (1.024-1.398)   0.024

  Black                                                         2696            534    1.562 (1.335-1.828)    \<0.001               1.630 (1.346-1.974)   \<0.001

  Unknown                                                       156             20     NA                     NA                    2.143 (1.058-4.343)   0.034

  Sex                                                                                                                                                     

  Female                                                        7668            1014   1 (Reference)          NA                    1 (Reference)         NA

  Male                                                          13093           2493   1.301 (1.186-1.428)    \<0.001               1.347 (1.205-1.505)   \<0.001

  Original                                                                                                                                                

  Hispanic                                                      4234            598    1 (Reference)          NA                    1 (Reference)         NA

  Non-Hispanic                                                  16527           2909   1.200 (1.067-1.350)    0.002                 1.302 (1.132-1.498)   \<0.001

  Tumor location                                                                                                                                          

  Upper                                                         7617            1628   1 (Reference)          NA                    1 (Reference)         NA

  Middle                                                        1978            274    0.761 (0.650-0.890)    0.001                 0.655 (0.542-0.791)   \<0.001

  Lower                                                         4397            534    0.703 (0.621-0.795)    \<0.001               0.675 (0.578-0.787)   \<0.001

  Overlapping lesion                                            1585            234    0.769 (0.649-0.912)    0.003                 0.534 (0.439-0.650)   \<0.001

  Unknown                                                       5184            837    0.700 (0.627-0.782)    \<0.001               0.578 (0.506-0.660)   \<0.001

  Pathology grade                                                                                                                                         

  I                                                             949             68     1 (Reference)          NA                    1 (Reference)         NA

  II                                                            4537            897    3.058 (2.328-4.018)    \<0.001               1.522 (1.035-2.237)   0.033

  III                                                           11177           1705   2.544 (1.946-3.327)    \<0.001               0.901 (0.619-1.311)   0.586

  IV                                                            317             36     2.160 (1.364-3.420)    0.001                 0.817 (0.458-1.455)   0.492

  Unknown                                                       3781            801    2.624 (1.992-3.456)    \<0.001               0.988 (0.673-1.451)   0.951

  Lauren classification                                                                                                                                   

  Diffuse-type                                                  5957            444    1 (Reference)          NA                    1 (Reference)         NA

  Intestinal-type                                               14264           2973   3.234 (2.876-3.637)    \<0.001               3.847 (3.395-4.358)   \<0.001

  Others^b^                                                     540             90     2.172 (1.644-2.870)    \<0.001               3.442 (2.458-4.819)   \<0.001

  T staging^c^                                                                                                                                            

  T1                                                            4977            728    1 (Reference)          NA                    1 (Reference)         NA

  Tis                                                           129             16     1.357 (0.764-2.410)    0.297                 0.686 (0.300-1.570)   0.373

  T2                                                            1785            97     0.311 (0.247-0.391)    \<0.001               0.448 (0.338-0.592)   \<0.001

  T3                                                            5038            400    0.388 (0.335-0.448)    \<0.001               0.555 (0.463-0.666)   \<0.001

  T4                                                            3883            641    1.121 (0.977-1.286)    0.103                 0.742 (0.629-0.874)   \<0.001

  Unknown                                                       4949            1625   1.884 (1.678-2.115)    \<0.001               NA                    NA

  N staging^c^                                                                                                                                            

  N0                                                            9355            1183   1 (Reference)          NA                    1 (Reference)         NA

  N1                                                            5541            1314   1.977 (1.786-2.187)    \<0.001               1.133 (1.005-1.278)   0.042

  N2                                                            1852            172    1.015 (0.839-1.226)    0.881                 0.866 (0.685-1.095)   0.229

  N3                                                            1953            149    0.886 (0.723-1.085)    0.241                 0.762 (0.599-0.970)   0.027

  Unknown                                                       2060            689    1.769 (1.555-2.014)    \<0.001               1.126 (0.972-1.305)   0.114

  Tumor size, cm                                                                                                                                          

  0-1                                                           955             51     1 (Reference)          NA                    1 (Reference)         NA

  1-2                                                           1502            100    1.332 (0.915-1.938)    0.135                 NA                    NA

  2-5                                                           5167            666    2.628 (1.900-3.633)    \<0.001               NA                    NA

  5+                                                            4041            617    3.419 (2.462-4.748)    \<0.001               NA                    NA

  Unknown                                                       9096            2073   3.351 (2.442-4.598)    \<0.001               NA                    NA

  Extrahepatic metastatic sites to bone, lung, and brain, No.                                                                                             

  0                                                             18406           2432   1 (Reference)          NA                    1 (Reference)         NA

  1                                                             1657            669    2.842 (2.522-3.202)    \<0.001               0.728 (0.644-0.824)   \<0.001

  2                                                             265             136    4.416 (3.371-5.785)    \<0.001               1.205 (0.918-1.581)   0.179

  3                                                             17              11     5.323 (1.773-15.980)   0.003                 1.495 (0.502-4.452)   0.470

  Unknown                                                       416             259    6.889 (5.497-8.634)    \<0.001               2.654 (2.075-3.394)   \<0.001

  Marital status                                                                                                                                          

  Married                                                       11782           2032   1 (Reference)          NA                    1 (Reference)         NA

  Single                                                        3257            584    NA                     NA                    NA                    NA

  Divorced                                                      1737            308    NA                     NA                    NA                    NA

  Widowed                                                       2888            432    NA                     NA                    NA                    NA

  Unknown                                                       1097            151    NA                     NA                    NA                    NA

  Residence type                                                                                                                                          

  Rural                                                         1546            290    1 (Reference)          NA                    1 (Reference)         NA

  Urban                                                         346             48     NA                     NA                    NA                    NA

  Metropolitan                                                  18869           3169   NA                     NA                    NA                    NA

  Insurance situation                                                                                                                                     

  Yes                                                           19271           3229   1 (Reference)          NA                    1 (Reference)         NA

  No                                                            960             197    1.680 (1.215-2.325)    0.002                 NA                    NA

  Unknown                                                       530             81     1.438 (1.094-1.891)    0.009                 NA                    NA

  Bachelor education\                                           20761           3057   1 (Reference)          NA                    1 (Reference)         NA
  (per 10% increase)                                                                                                                                      

  Current smoking status\                                       20761           3057   1.161 (1.046-1.288)    0.005                 1 (Reference)         NA
  (per 10% increase)                                                                                                                                      

  Ever smoking status\                                          20761           3057   1 (Reference)          NA                    1 (Reference)         NA
  (per 10% increase)                                                                                                                                      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations:

CI: confidence interval, OR: odds ratio, GCLM: gastric cancer with liver metastases;

^a^ including Asian and American Indians;

^b^ including linitis plastica, hepatoid adenocarcinoma, adenosquamous carcinoma;

^c^ according to the seventh edition of the AJCC Cancer Staging manual.

###### 

Multivariable Cox Regression for All-Cause Mortality Among Patients With Liver Metastases.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                      Patients, No.          All-Cause Mortality (Model 1)             All-Cause Mortality (Model 2)   
  ------------------------------------------------------------- --------------- ------ ------------------------------- --------- ------------------------------- ---------
  Year at diagnosis                                                                                                                                              

  2010                                                          4005            696    1 (Reference)                   NA        1 (Reference)                   NA

  2011                                                          3982            700    NA                              NA        NA                              NA

  2012                                                          4280            671    NA                              NA        NA                              NA

  2013                                                          4233            745    NA                              NA        NA                              NA

  2014                                                          4333            695    NA                              NA        NA                              NA

  Age at diagnosis, Y                                                                                                                                            

  80+                                                           3615            505    1 (Reference)                   NA        1 (Reference)                   NA

  18-40                                                         929             118    0.798 (0.630-0.997)             0.047     0.808 (0.638-1.022)             0.076

  41-65                                                         8818            1588   0.746 (0.660-0.843)             \<0.001   0.748 (0.662-0.845)             \<0.001

  66-80                                                         7399            1296   0.834 (0.742-0.937)             0.002     0.838 (0.746-0.941)             0.003

  Tumor location                                                                                                                                                 

  Upper                                                         7617            1628   1 (Reference)                   NA        1 (Reference)                   NA

  Middle                                                        1978            274    1.011 (0.876-1.167)             0.881     1.027 (0.890-1.186)             0.714

  Lower                                                         4397            534    0.948 (0.845-1.064)             0.364     0.963 (0.859-1.080)             0.520

  Overlapping lesion                                            1585            234    1.292 (1.111-1.503)             0.001     1.289 (1.108-1.499)             0.001

  Unknown                                                       5184            837    0.999 (0.908-1.099)             0.989     1.009 (0.917-1.110)             0.862

  Lauren classification                                                                                                                                          

  Intestinal-type                                               14264           2973   1 (Reference)                   NA        1 (Reference)                   NA

  Diffuse-type                                                  5957            444    1.204 (1.076-1.348)             0.001     1.200 (1.072-1.343)             0.001

  Others^a^                                                     540             90     1.476 (1.178-1.850)             0.001     1.440 (1.149-1.805)             0.002

  T staging^b^                                                                                                                                                   

  T1                                                            4977            728    1 (Reference)                   NA        1 (Reference)                   NA

  Tis                                                           129             16     1.213 (0.613-2.397)             0.579     1.234 (0.624-2.439)             0.546

  T2                                                            1785            97     0.712 (0.559-0.906)             0.006     0.708 (0.556-0.902)             0.005

  T3                                                            5038            400    0.906 (0.781-1.051)             0.194     0.902 (0.777-1.047)             0.174

  T4                                                            3883            641    1.075 (0.952-1.214)             0.244     1.073 (0.950-1.211)             0.257

  Unknown                                                       4949            1625   0.999 (0.904-1.104)             0.989     1.001 (0.906-1.107)             0.979

  N staging^b^                                                                                                                                                   

  N0                                                            9355            1183   1 (Reference)                   NA        1 (Reference)                   NA

  N1                                                            5541            1314   NA                              NA        NA                              NA

  N2                                                            1852            172    NA                              NA        NA                              NA

  N3                                                            1953            149    NA                              NA        NA                              NA

  Unknown                                                       2060            689    NA                              NA        NA                              NA

  Surgery                                                                                                                                                        

  Gastrectomy                                                   7981            223    1 (Reference)                   NA        NA                              NA

  RGCWROO^c^                                                    952             29     0.654 (0.384-1.114)             0.118     NA                              NA

  No                                                            11273           3234   1.899 (1.574-2.293)             \<0.001   NA                              NA

  Refuse                                                        555             21     1.813 (1.109-2.965)             0.018     NA                              NA

  Radiotherapy                                                                                                                                                   

  Yes                                                           5484            542    1 (Reference)                   NA        NA                              NA

  No                                                            15277           2965   1.037 (0.930-1.156)             0.512     NA                              NA

  Chemotherapy                                                                                                                                                   

  Yes                                                           10782           1869   1 (Reference)                   NA        NA                              NA

  No                                                            9979            1638   3.064 (2.818-3.332)             \<0.001   NA                              NA

  Sequence of radiotherapy and surgery^d^                                                                                                                        

  RBS                                                           1127            14     1 (Reference)                   NA        1 (Reference)                   NA

  RAS                                                           1952            45     NA                              NA        NA                              NA

  RBAS                                                          45              1      NA                              NA        NA                              NA

  Others                                                        17637           3447   NA                              NA        NA                              NA

  Treatment^e^                                                                                                                                                   

  Others                                                        5242            1364   NA                              NA        1 (Reference)                   NA

  RSC                                                           2781            30     NA                              NA        0.217 (0.138-0.340)             \<0.001

  RS                                                            130             5      NA                              NA        0.419 (0.155-1.136)             0.087

  SC                                                            1969            96     NA                              NA        0.192 (0.147-0.256)             \<0.001

  RC                                                            1975            359    NA                              NA        0.339 (0.294-0.390)             \<0.001

  R                                                             598             148    NA                              NA        0.753 (0.631-0.899)             0.002

  S                                                             4001            121    NA                              NA        0.419 (0.332-0.528)             \<0.001

  C                                                             4065            1384   NA                              NA        0.299 (0.272-0.327)             \<0.001

  Tumor size, cm                                                                                                                                                 

  0-1                                                           955             51     1 (Reference)                   NA        1 (Reference)                   NA

  1-2                                                           1502            100    NA                              NA        NA                              NA

  2-5                                                           5167            666    NA                              NA        NA                              NA

  5+                                                            4041            617    NA                              NA        NA                              NA

  Unknown                                                       9096            2073   NA                              NA        NA                              NA

  Extrahepatic metastatic sites to bone, lung, and brain, No.                                                                                                    

  0                                                             18406           2432   1 (Reference)                   NA        1 (Reference)                   NA

  1                                                             1657            669    1.362 (1.240-1.497)             \<0.001   1.370 (1.247-1.505)             \<0.001

  2                                                             265             136    1.476 (1.212-1.798)             \<0.001   1.495 (1.227-1.821)             \<0.001

  3                                                             17              11     0.798 (0.423-1.505)             0.485     0.763 (0.405-1.441)             0.405

  Unknown                                                       416             259    1.151 (1.001-1.324)             0.048     1.152 (1.002-1.324)             0.047

  Marital status                                                                                                                                                 

  Married                                                       11782           2032   1 (Reference)                   NA        1 (Reference)                   NA

  Single                                                        3257            584    1.150 (1.038-1.274)             0.008     1.144 (1.033-1.267)             0.010

  Divorced                                                      1737            308    1.153 (1.012-1.314)             0.033     1.152 (1.011-1.312)             0.034

  Widowed                                                       2888            432    0.962 (0.851-1.087)             0.535     0.961 (0.850-1.086)             0.525

  Unknown                                                       1097            151    0.858 (0.711-1.036)             0.112     0.847 (0.701-1.022)             0.083

  Residence type                                                                                                                                                 

  Rural                                                         1546            290    1 (Reference)                   NA        1 (Reference)                   NA

  Urban                                                         346             48     NA                              NA        NA                              NA

  Metropolitan                                                  18869           3169   NA                              NA        0.858 (0.743-0.990)             0.036

  Bachelor education\                                           20761           3057   1                               NA        1                               NA
  (per 10% increase)                                                                                                                                             

  Median household income\                                      20761           3057   1                               NA        1                               NA
  (per \$ 20,000 increase)                                                                                                                                       

  Current smoking status\                                       20761           3057   1                               NA        1                               NA
  (per 10% increase)                                                                                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations:

CI: confidence interval, GCLM: gastric cancer with liver metastases;

^a^ including linitis plastica, hepatoid adenocarcinoma, adenosquamous carcinoma;

^b^according to the seventh edition of the AJCC Cancer Staging manual;

^c^ RGCWROO: radical gastrectomy in continuity with the resection of other organs;

^d^ including RBS: radiotherapy before surgery, RAS: radiotherapy after surgery, RBAS: radiotherapy before and after surgery, others: without radiotherapy or surgery or unknown sequence;

^e^ including RSC: radiotherapy, surgery and chemotherapy, RS: radiotherapy and surgery, SC: chemotherapy and surgery, RC: radiotherapy and chemotherapy, R: only radiotherapy, S: only surgery, C: only chemotherapy, others: other treatment except for radiotherapy, surgery and chemotherapy.
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